表紙
市場調査レポート

出血性疾患:世界の医薬品産業・市場

Bleeding Disorders: World Pharmaceutical Industry and Market 2014-2024

発行 Visiongain Ltd 商品コード 291016
出版日 ページ情報 英文 130 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=137.27円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。
制限内容は、上記ライセンスの[?]アイコンをクリックしてご確認ください。

Back to Top
出血性疾患:世界の医薬品産業・市場 Bleeding Disorders: World Pharmaceutical Industry and Market 2014-2024
出版日: 2013年12月09日 ページ情報: 英文 130 Pages
概要

当レポートでは、世界の出血性疾患治療薬市場について調査し、市場動向、R&Dの展望および売上予測を提供しており、世界市場全体、2次市場(血友病A・B、血小板減少症、関連疾患)、10製品および主要11国ヵの取引予測、収益予測、成長率と市場シェアなどを、概略下記の構成でお届けいたします。

第1章 エグゼクティブサマリー

第2章 出血性疾患のイントロダクション

第3章 世界の出血性疾患向け医薬品市場

  • 世界の出血性疾患向け医薬品市場
  • 出血性疾患向け医薬品市場:全体的な収益予測
  • 出血性疾患別の医薬品市場:収益・市場シェアの比較
  • 世界の治療サブクラス別による医薬品市場:分類別の収益予測
  • 血友病Aは市場の約70%を占める:2012年
  • 血友病Bは出血性疾患市場で突出して増加
  • 血小板減少症
  • その他の凝固因子欠乏
  • 調査・分析のサマリー

第4章 主な出血性疾患向け医薬品市場

  • 主な出血性疾患治療薬
  • 主な出血性疾患治療薬:収益・市場シェアの比較
  • 主な出血性疾患治療薬:分類別の収益予測
  • Advateが引き続き市場で優勢を保つ
  • NovoSeven:特許権保護が失効するが、収益生成は好調を維持
  • Kogenate:無針デリバリーが患者にとって魅力的なオプションに
  • BeneFIX は競合に直面:収益にどう影響するか?
  • FEIBA:阻害剤による疾病治療の元祖
  • ReFacto/ Xyntha:完全に人工の精製工程を用いた生産
  • Helixate:Bayerとのマーケティング合意を2017年まで延長
  • Nplate:血小板減少症でトップの主要製品-2012年
  • Alphanate:1978年以降、出血性疾患の主要な治療薬
  • Promactaと Nplateの競合、どちらが最も成功を証明するか?
  • 開発パイプラインにおける有望な化合物

第5章 主要国の出血性疾患向け医薬品市場

  • 主要国市場:米国が優位に立つ-2012年
  • 主要国市場:収益・市場シェアの比較
  • 主要国市場:分類別の収益予測
  • 米国が予測期間を通して引き続き出血性疾患市場における優勢を保つ見込み
  • EU5カ国:展望は?
  • 日本
  • 中国
  • ブラジル
  • インド
  • ロシア

第6章 出血性疾患:R&Dパイプライン

  • R&Dパイプラインの概要
  • 事前登録された4つの候補薬
  • 第3相開発パイプライン:Novo Nordisk が強いプレゼンスを持つ
  • 第2/第3相開発パイプライン:豊富な血友病A治療薬
  • 第1/第2相開発パイプライン:血友病Bの遺伝子治療
  • 第1相開発パイプライン:Novo NordiskおよびPfizerからの提供

第7章 主要企業

第8章 定性分析

  • 強み・弱み
  • 機会
  • 社会、技術、経済、および政治的影響因子

第9章 調査インタビュー

第10章 結論

  • 世界の出血性疾患向け医薬品市場
  • 出血性疾患:主な上市薬
  • 主要国市場
  • 産業・市場動向

第11章 用語集

図表

目次

Treating abnormal bleeding - this new report shows you trends, R&D outlooks, and sales forecasts

Treatments for bleeding - what're their prospects? Visiongain's new report gives you predictions for drugs controlling those blood clotting diseases. Stay ahead then. You discover financial results, technologies, R&D trends, opportunities, and forecasted revenues.

So you see what's possible for treating haemophilia (hemophilia) and other blood-coagulation disorders. Avoid missing out. You get data and analysis for that industry and market, assessing outlooks. You find business analysis, progress, and potential gains.

Hear what lies ahead for those products, benefiting your work and influence. Read on, then, to explore those medicines and see what their future could be worth.

Forecasts and other information explaining lucrative possibilities for treatments

Our study reveals trade predictions to 2024 at overall world, submarket, product, and national level. For those therapies, you investigate where the money lies. Find potentials.

Besides revenue forecasting from 2013 to 2024, that new work shows historical findings, growth rates, and market shares. There you get feel for commercial outlooks and developments (R&D). You also gain an interview, 50 charts, and 78 tables.

Futures of medicines stopping and preventing haemorrhaging - data to help your work

Our study concludes that, from 2014, patients, healthcare providers, and pharma companies will gain from that medical and technological progress. Hear what's possible.

Find there how you can help your research, analyses, and decisions. Also save time. And discover how you could benefit your authority through better understanding the future.

So the following sections explain what you get in our new investigation.

Forecasting of that world market and its main segments - see what's likely to happen

What's that industry's potential? What're the secrets of its progress? Discover in our report overall world revenue to 2024 for pharmaceuticals controlling bleeding.

Also you see individual revenue predictions to 2024 for four therapeutic submarkets at world level:

  • Haemophilia A
  • Haemophilia B
  • Thrombocytopenia
  • Related diseases (other coagulation factor deficiencies, grouped).

How will those markets expand? Which classes of therapy will generate most money? So you assess outlooks for sales growth, seeing where you can gain.

There you explore competition and rising sales. Also you assess products' futures.

Predicting of existing and expected therapies' revenues

Find sales outlooks for top brands, too, seeing how they compete and succeed. Our study shows you individual revenue forecasts to 2024 for 10 marketed products, including these:

  • Advate
  • NovoSeven
  • Kogenate
  • BeneFIX
  • FEIBA.

You also get revenue predictions for five expected agents, including these:

  • Rixubis
  • Eloctate
  • Alprolix.

There you find drugs and years with highest predicted sales rises. Also you examine competitors. You see what's happening, then, understanding challenges, competition, opportunities, and successes.

Our work also divides its overall prediction into geographical regions.

Healthcare in national markets - what outlooks for business?

In developed and developing countries, opportunities for providers of those products and technologies will occur from 2014 to 2024. See where and how, finding sales potentials.

Our analyses show you individual revenue forecasts to 2024 for 11 national markets:

  • United States (US)
  • Japan
  • Germany, France, UK, Italy, and Spain (EU5)
  • Brazil, Russia, India, and China (BRIC nations).

There you find places with highest revenues and potential sales growth. Our work explains. You assess international prospects for modifying bleeding control, preventing excessive blood loss, also appraising needs and demands.

Explore, too, how that haematological technology benefits developers, producers, marketers, and sellers. Our work shows you, discussing issues.

Events and forces for developing, producing, marketing, and selling blood-stemming drugs

The report shows you issues and events affecting that industry from 2014, including these:

  • Advances in understanding haemostasis and coagulation aiding science and product development
  • Needle-free drug delivery and other innovations
  • Synthetic purification processes and other novel techniques for making biologics and biosimilars
  • Long-acting clotting factor therapy and recombinant coagulation factors
  • Use of prophylactic schedules (prophylaxis) increasing
  • Regulators, pricing, and other challenges - approvals, costs, and concerns.

There you explore political, economic, social, and technological questions, investigating outlooks for business. Discover what the future holds.

Examine, then, what stimulates and restrains players in that industry and affects results.

Companies and overall 2017 market value - find outlook for success

What happens next? From 2014 new treatments there and improving healthcare in rising countries encourage investments, medical advances, and higher revenues.

So our report predicts the world drugs market for preventing haemorrhages will generate $13.5bn in 2017. There, large medical firms and biopharma specialists can win. See how.

In particular, then, you explore activities and prospects of these companies:

  • Baxter
  • Novo Nordisk
  • Bayer
  • Pfizer
  • CSL Behring.

R&D in that industry holds strengths, and from 2014 there will arise many opportunities. This decade onwards, then, patients, payers, and companies will benefit.

And you discover how that market can perform, staying ahead in knowledge.

Ways Bleeding Disorders: World Pharmaceutical Industry and Market 2014-2024 helps

In particular, our new investigation gives you these advantages:

  • Revenues there to 2024 at world level, for 4 submarkets, and 15 products - assess outlooks for production, marketing, and sales
  • Forecasts to 2024 for 11 national markets in the Americas, Europe, and Asia - examine developed and developing countries for potential revenues
  • Prospects for established competitors, emerging companies, and new entrants - investigate portfolios, results, strategies, developmental activities, and successes.

Information found nowhere else, helping your searches, analyses, and decisions

Our new study gives independent analysis. There you receive competitive intelligence found only in our work, finding where progress and money lie. Explore commercial possibilities.

With that data you're less likely to fall behind in information or miss opportunity. Being free to choose, you find how you could save time and effort with our study, aiding your decisions.

You discover original insights then. So act now in advance of your rivals, also benefiting your authority.

Table of Contents

1. Executive Summary

  • 1.1 What This Report Covers
  • 1.2 Bleeding Disorders: World Pharma Industry and Market Overview 2013-2024
  • 1.3 Chapter Outlines
  • 1.4 Research and Analysis Methods

2. Introduction to Bleeding Disorders

  • 2.1 Understanding Haemostasis and Coagulation
    • 2.1.1 Vascular Spasm
    • 2.1.2 Platelet Activation and Aggregation
    • 2.1.3 Coagulation
  • 2.2 An Introduction to the Bleeding Disorders and Their Treatment
    • 2.2.1 Haemophilia A, B and C
    • 2.2.2 Von Willebrand Disease
    • 2.2.3 Thrombocytopenia

3. The World Pharmaceutical Market for Bleeding Disorders 2014-2024

  • 3.1 The World Pharmaceutical Market for Bleeding Disorders in 2012
  • 3.2 The Bleeding Disorders Pharmaceutical Market: An Overarching Revenue Forecast 2014-2024
  • 3.3 The Pharmaceutical Market by Bleeding Disorder: Comparison of Revenue and Market Share, 2018 and 2024
  • 3.4 The World Pharmaceutical Market for Bleeding Disorders by Therapeutic Subclass: Grouped Revenue Forecasts 2014-2024
  • 3.5 Haemophilia A Accounted for Almost 70% of the Market in 2012
  • 3.6 Haemophilia B Will See Increasing Prominence in the Bleeding Disorders Market
  • 3.7 Thrombocytopenia
  • 3.8 Other Coagulation Factor Deficiencies
  • 3.9 Summary of the Research and Analyses

4. Leading Drugs of the Market for Treating Bleeding Disorders, 2014-2024

  • 4.1 The Leading Drugs for the Treatment of Bleeding Disorders in 2012
  • 4.2 Leading Bleeding Disorder Drugs: Comparison of Revenue and Market Share, 2018 and 2024
  • 4.3 Leading Bleeding Disorder Drugs: A Grouped Revenue Forecast, 2014-2024
  • 4.4 Advate Will Continue to Dominate the Market
  • 4.5 NovoSeven: Patent Protection Has Expired, But Revenue Generation Remains Strong
  • 4.6 Kogenate: Needle-Free Delivery Makes it an Attractive Option for Patients
  • 4.7 BeneFIX Faces Competition in 2013 - How Will This Affect Revenue?
  • 4.8 FEIBA: The Original Treatment for Disease with Inhibitors
  • 4.9 ReFacto/ Xyntha: Produced Using an Entirely Synthetic Purification Process
  • 4.10 Helixate: Marketing Agreement With Bayer Extends Until 2017
  • 4.11 Nplate: The Leading Product for Thrombocytopenia in 2012
  • 4.12 Alphanate: A Staple Treatment for Bleeding Disorders Since 1978
  • 4.13 Promacta Competes With Nplate, But Which Will Prove Most Successful?
  • 4.14 Promising Compounds in the Developmental Pipeline
    • 4.14.1 Rixubis: The First Recombinant FIX Treatment Factor for Routine Prophylaxis in Haemophilia B
    • 4.14.2 Eloctate: The First Long-Acting Clotting Factor Therapy for Haemophilia A?
    • 4.14.3 Alprolix: The First Long-Acting Clotting Factor Treatment for Haemophilia B?
    • 4.14.4 N8-GP: Novo Nordisk's Long Acting Compound for the Treatment of Haemophilia A
    • 4.14.5 N9-GP: Novo Nordisk's Long-Acting Treatment for Haemophilia B

5. The Leading National Pharmaceutical Markets for Bleeding Disorders, 2014-2024

  • 5.1 The Leading National Markets for Bleeding Disorders: The US Dominates in 2012
  • 5.2 The Leading National Markets: Comparison of Revenue and Market Share, 2018 and 2024
  • 5.3 Leading National Pharmaceutical Markets for Bleeding Disorders: Grouped Revenue Forecasts, 2014-2024
  • 5.4 The US Will Continue to Dominate the Bleeding Disorders Market Throughout the Forecast Period
  • 5.5 The EU5: What Prospects There?
    • 5.5.1 Germany Will Remain the Largest of the EU5 Markets
    • 5.5.2 France: Increasing Uptake of Prophylactic Therapy Will Drive Growth
    • 5.5.3 Italy: The 3rd Largest Market of the EU5
    • 5.5.4 The UK: Well Developed Infrastructure for the Treatment of Bleeding Disorders
    • 5.5.5 Spain: Use of Recombinant Coagulation Factors is Relatively Low at Present
  • 5.6 Japan: Use of Prophylactic Treatment is Lower Than That of the Western World
  • 5.7 China: A Growing Domestic Bleeding Disorders Pharmaceutical Market
  • 5.8 Brazil: Baxter Will Be the Exclusive Provider of Recombinant Therapy for the Next 10 Years
  • 5.9 India: 90% of Patients Are Unable to Afford Treatment Costs
  • 5.10 Russia: Treatment Levels Per Capita Are High

6. Bleeding Disorders: R&D Pipelines, 2013

  • 6.1 The R&D Pipeline for Bleeding Disorders: An Overview
  • 6.2 Four Candidates Are In Pre-Registration
    • 6.2.1 Novo Nordisk's NovoEight
    • 6.2.2 Novo Nordisk's NovoThirteen: Denied Approval by the FDA for the Second Time; Will It Be Third Time Lucky?
    • 6.2.3 Biogen Idec's Eloctate: The First Long-Acting Treatment for Haemophilia A?
    • 6.2.4 Biogen Idec's Alprolix: The First Long-Acting Treatment for Haemophilia B?
  • 6.3 The Phase III Development Pipeline: Novo Nordisk Has a Strong Presence
    • 6.3.1 Novo Nordisk's N8-GP and N9-GP: Second in Class Treatments?
    • 6.3.2 Baxter's rFVIIa BI
    • 6.3.3 Octapharma's Human-cl rhFVIII
  • 6.4 The Phase II/III Development Pipeline: An Abundance of Haemophilia A Treatments
    • 6.4.1 Baxter's BAX855: Another Long-Acting Haemophilia A Treatment
    • 6.4.2 Baxter has Purchased OBI-1 from Inspiration Biopharmaceuticals
  • 6.5 The Phase I/II Development Pipeline: Gene Therapy for Haemophilia B
  • 6.6 The Phase I Development Pipeline: Offerings from Novo Nordisk and Pfizer
    • 6.6.1 Novo Nordisk's mAb2021
    • 6.6.2 Pfizer's PF-05280602

7. Leading Companies of the Bleeding Disorders Pharmaceutical Market

  • 7.1 The Leading Companies of the Bleeding Disorders Pharmaceutical Market
  • 7.2 Baxter Accounted for Over 30% of the Bleeding Disorders Market in 2012, But Will It Remain Market Leader?
  • 7.3 Novo Nordisk: Demonstrating Commitment to Treating Bleeding Disorders
  • 7.4 Bayer: A Limited Product Portfolio?
  • 7.5 Pfizer: Declining Market Share During the Forecast Period?
  • 7.6 CSL Behring Has the largest Portfolio of Bleeding Disorder Drugs
  • 7.7 Grifols Will Have a Declining Market Share
  • 7.8 Amgen: Single Stake in the Bleeding Disorders Market
  • 7.9 Octapharma: Branching Into Recombinant Coagulation Factors
  • 7.10 GSK: Bleeding Disorders Are Not a Main Therapeutic Focus
  • 7.11 Biogen Idec: Market Entry Anticipated in 2014

8. Qualitative Analysis of the Bleeding Disorders Pharmaceutical Market, 2013-2024

  • 8.1 Strengths and Weaknesses of the Bleeding Disorders Pharmaceutical Market, 2013
    • 8.1.1 Treatment of Bleeding is Essential
    • 8.1.2 The Threat of Generic/Biosimilar Competition is Low
    • 8.1.3 Advances in Technology Have Improved Treatment Options
    • 8.1.4 A Small Patient Population Ultimately Restricts the Market
    • 8.1.5 Emerging National Markets: Patients Often Having Little Access to Treatments
    • 8.1.6 High Barriers to Market Entry
    • 8.1.7 The Burden of Prophylactic Therapy
  • 8.2 The Opportunities and Threats Facing the Market, 2014-2024
    • 8.2.1 Low Switch Rate Among Patients Receiving Treatment for Bleeding Disorders: An Opportunity and a Threat
    • 8.2.2 Demand for Treatment in the Emerging Markets is Increases, But Are Recombinant Therapies Too Expensive?
    • 8.2.3 High Barriers to Market Entry Will Limit Competition, But Also Limit Development
  • 8.3 Social, Technological, Economic and Political Forces Influencing the Bleeding Disorders Pharmaceutical Market, 2014-2024
    • 8.3.1 Social Factors
    • 8.3.2 Technological Factors
    • 8.3.3 Economic Factors
    • 8.3.4 Political Factors

9. Research Interview

  • 9.1 Interview With Dr Kamran Kamyar, M.D., Medical Manager, AryoGen Biopharma
    • 9.1.1 On the State of the Current Market
    • 9.1.2 On AryoGen's Presence in the Market
    • 9.1.3 On Important Developments in the Industry

10. Conclusions from Our Study

  • 10.1 The World Pharmaceutical Market for Bleeding Disorders, 2014-2024
  • 10.2 Bleeding Disorders: Leading Products on the Market, 2014-2024
  • 10.3 Leading National Markets for the Bleeding Disorder Pharmaceutical Industry, 2014-2024
  • 10.4 Trends in that Industry and Market
    • 10.4.1 Bleeding Disorders Are Serious Conditions Requiring Frequent Drug Treatment
    • 10.4.2 The Demand for Drug Treatment Is Increasing
    • 10.4.3 The R&D Pipeline is Well Stocked, But What Does This Mean for the Industry?

List of Tables

  • Table 1.1 Currency Exchange Rates
  • Table 2.1 The Coagulation Factors: Compound Name, Associated Bleeding Disorder and Bleeding Severity
  • Table 2.2 Treatment for VWD: Drug, Mechanism of Action and Disease Type
  • Table 3.1 The World Pharmaceutical Market for Bleeding Disorders by Disorder: Revenues ($m) and Market Shares (%), 2012
  • Table 3.2 The Pharmaceutical Market for Bleeding Disorders: Overarching Revenue Forecast ($m), 2013-2024
  • Table 3.3 The World Market by Bleeding Disorder: Comparison of Revenues ($m) and Market Shares (%), 2018 and 2024
  • Table 3.4 The World Market for Bleeding Disorders by Disorder: Grouped Revenue ($m) and Market Share (%) Forecasts, 2013-2024
  • Table 3.5 Haemophilia A: Revenue ($m) and Market Share (%) Forecast, 2013-2024
  • Table 3.6 Haemophilia B: Revenue ($m) and Market Share (%) Forecast, 2013-2024
  • Table 3.7 Thrombocytopenia: Revenue ($m) and Market Share (%) Forecast, 2013-2024
  • Table 3.8 Other Coagulation Factor Deficiencies: Revenue ($m) and Market Share (%) Forecast, 2013-2024
  • Table 4.1 The Leading Drugs of the Bleeding Disorders Pharmaceutical Market: Revenues ($m) and Market Shares (%), 2012
  • Table 4.2 The Leading Drugs for the Bleeding Disorders: Comparison of Revenues ($m) and Market Shares (%), 2018 and 2024
  • Table 4.3 Leading Drugs: Grouped Revenue Forecasts ($m), 2013-2024
  • Table 4.4 Advate: Key Facts
  • Table 4.5 Advate: Revenue ($m) and Market Share (%) Forecast, 2013-2024
  • Table 4.6 NovoSeven: Key Facts
  • Table 4.7 NovoSeven: Revenue ($m) and Market Share (%) Forecast, 2013-2024
  • Table 4.8 Kogenate: Key Facts
  • Table 4.9 Kogenate: Revenue ($m) and Market Share (%) Forecast, 2013-2024
  • Table 4.10 BeneFIX: Key Facts
  • Table 4.11 BeneFIX: Revenue ($m) and Market Share (%) Forecast, 2013-2024
  • Table 4.12 FEIBA: Key Facts
  • Table 4.13 FEIBA: Revenue ($m) and Market Share (%) Forecast, 2013-2024
  • Table 4.14 ReFacto/ Xyntha: Key Facts
  • Table 4.15 ReFacto/ Xyntha: Revenue ($m) and Market Share (%) Forecast, 2013-2024
  • Table 4.16 Helixate: Key Facts
  • Table 4.17 Helixate: Revenue ($m) and Market Share (%) Forecast, 2013-2024
  • Table 4.18 Nplate: Key Facts
  • Table 4.19 Nplate: Revenue ($m) and Market Share (%) Forecast, 2013-2024
  • Table 4.20 Alphanate: Key Facts
  • Table 4.21 Alphanate: Revenue ($m) and Market Share (%) Forecast, 2013-2024
  • Table 4.22 Promacta: Key Facts
  • Table 4.23 Promacta: Revenue ($m) and Market Share (%) Forecast, 2013-2024
  • Table 4.24 Rixubis: Key Facts
  • Table 4.25 Rixubis: Revenue ($m) and Market Share (%) Forecast, 2013-2024
  • Table 4.26 Eloctate: Key Facts
  • Table 4.27 Eloctate: Revenue ($m) and Market Share (%) Forecast, 2013-2024
  • Table 4.28 Alprolix: Key Facts
  • Table 4.29 Alprolix: Revenue ($m) and Market Share (%) Forecast, 2013-2024
  • Table 4.30 N8-GP: Key Facts
  • Table 4.31 N8-GP: Revenue ($m) and Market Share (%) Forecast, 2013-2024
  • Table 4.32 N9-GP: Key Facts
  • Table 4.33 N9-GP: Revenue ($m) and Market Share (%) Forecast, 2013-2024
  • Table 5.1 Leading National Markets for Bleeding Disorders: Revenues ($m) and Market Shares (%), 2012
  • Table 5.2 The Leading National Markets: Comparison of Revenues ($m) and Market Shares (%), 2018 and 2024
  • Table 5.3 The Leading National Markets for Bleeding Disorders: Grouped Revenue Forecasts ($m), 2013-2024
  • Table 5.4 The US Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024
  • Table 5.5 The EU5 Bleeding Disorders Market by Country: Revenue ($m) and Market Share (%) Forecasts, 2013-2024
  • Table 5.6 The German Bleeding Disorder Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024
  • Table 5.7 The French Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024
  • Table 5.8 The Italian Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024
  • Table 5.9 The UK Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024
  • Table 5.10 The Spanish Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024
  • Table 5.11 The Japanese Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024
  • Table 5.12 The Chinese Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024
  • Table 5.13 The Brazilian Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024
  • Table 5.14 The Indian Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024
  • Table 5.15 The Russian Bleeding Disorders Market: Revenue ($m) and Market Share (%) Forecast, 2013-2024
  • Table 6.1 Bleeding Disorders: Candidates in Pre-Registration, 2013
  • Table 6.2 Bleeding Disorders: Candidates in Phase III Development, 2013
  • Table 6.3 Bleeding Disorders: Candidates in Phase II/III Development, 2013
  • Table 6.4 Bleeding Disorders: Candidates in Phase I/II Development, 2013
  • Table 6.5 Bleeding Disorders: Candidates in Phase I Development, 2013
  • Table 7.1 The Leading Companies of the Bleeding Disorders Market: Revenues ($m) and Market Shares (%), 2012
  • Table 7.2 Baxter: Product Portfolio for Bleeding Disorders, 2013
  • Table 7.3 Novo Nordisk: Bleeding Disorders Product Portfolio, 2013
  • Table 7.4 Bayer: Bleeding Disorders Product Portfolio, 2013
  • Table 7.5 Pfizer: Bleeding Disorders Product Portfolio, 2013
  • Table 7.6 CSL Behring: Bleeding Disorders Product Portfolio, 2013
  • Table 7.7 Grifols: Bleeding Disorders Product Portfolio, 2013
  • Table 7.8 Amgen: Bleeding Disorders Product Portfolio, 2013
  • Table 7.9 Octapharma: Bleeding Disorders Product Portfolio, 2013
  • Table 7.10 GlaxoSmithKline: Bleeding Disorders Product Portfolio, 2013
  • Table 7.11 Biogen Idec: Bleeding Disorders Product Portfolio, 2013
  • Table 8.1 Strengths and Weaknesses of the Bleeding Disorders Pharmaceutical Market, 2013
  • Table 8.2 Opportunities and Threats Facing the Bleeding Disorders Pharmaceutical Market, 2013-2024
  • Table 8.3 Social, Technological, Economic and Political Factors Influencing the Bleeding Disorders Market (STEP Analysis), 2013-2024

List of Figures

  • Figure 2.1 Diagram of the Coagulation Cascade
  • Figure 3.1 The World Pharmaceutical Market for Bleeding Disorders by Disorder: Market Shares (%), 2012
  • Figure 3.2 The Pharmaceutical Market for Bleeding Disorders: Overarching Revenue Forecast ($m), 2013-2024
  • Figure 3.3 The World Market by Bleeding Disorder: Market Shares (%), 2018
  • Figure 3.4 The World Market by Bleeding Disorder: Market Shares (%), 2024
  • Figure 3.5 Haemophilia A: Revenue Forecast ($m), 2013-2024
  • Figure 3.6 The Haemophilia A Submarket: Driving and Restraining Factors, 2013
  • Figure 3.7 Haemophilia B: Revenue Forecast ($m), 2013-2024
  • Figure 3.8 The Haemophilia B Submarket: Driving and Restraining Factors, 2013
  • Figure 3.9 Thrombocytopenia: Revenue Forecast ($m), 2013-2024
  • Figure 3.10 The Thrombocytopenia Submarket: Driving and Restraining Factors, 2013
  • Figure 3.11 Other Coagulation Factor Deficiencies: Revenue Forecast ($m), 2013-2024
  • Figure 4.1 Leading Drugs of the Bleeding Disorders Pharmaceutical Market: Market Shares (%), 2012
  • Figure 4.2 Leading Drugs for Bleeding Disorders: Market Shares (%), 2018
  • Figure 4.3 Leading Drugs for Bleeding Disorders: Market Shares (%), 2024
  • Figure 4.4 Advate: Revenue Forecast ($m), 2013-2024
  • Figure 4.5 NovoSeven: Revenue Forecast ($m), 2013-2024
  • Figure 4.6 Kogenate: Revenue Forecast ($m), 2013-2024
  • Figure 4.7 BeneFIX: Revenue Forecast ($m), 2013-2024
  • Figure 4.8 FEIBA: Revenue Forecast ($m), 2013-2024
  • Figure 4.9 ReFacto/ Xyntha: Revenue Forecast ($m), 2013-2024
  • Figure 4.10 Helixate: Revenue Forecast ($m), 2013-2024
  • Figure 4.11 Nplate: Revenue Forecast ($m), 2013-2024
  • Figure 4.12 Alphanate: Revenue Forecast ($m), 2013-2024
  • Figure 4.13 Promacta: Revenue Forecast ($m), 2013-2024
  • Figure 4.14 Rixubis: Revenue Forecast ($m), 2013-2024
  • Figure 4.15 Eloctate: Revenue Forecast ($m), 2013-2024
  • Figure 4.16 Alprolix: Revenue Forecast ($m), 2013-2024
  • Figure 4.17 N8-GP: Revenue Forecast ($m), 2013-2024
  • Figure 4.18 N9-GP: Revenue Forecast ($m), 2013-2024
  • Figure 5.1 Leading National Markets for Bleeding Disorders: Market Share (%), 2012
  • Figure 5.2 Leading National Markets for Bleeding Disorders: Market Shares (%), 2018
  • Figure 5.3 Leading National Markets for Bleeding Disorders: Market Share (%), 2024
  • Figure 5.4 The US Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024
  • Figure 5.5 The EU5 Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024
  • Figure 5.6 The German Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024
  • Figure 5.7 The French Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024
  • Figure 5.8 The Italian Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024
  • Figure 5.9 The UK Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024
  • Figure 5.10 The Spanish Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024
  • Figure 5.11 The Japanese Bleeding Disorders Market: Revenue Forecast ($m) 2013-2024
  • Figure 5.12 The Chinese Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024
  • Figure 5.13 The Brazilian Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024
  • Figure 5.14 The Indian Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024
  • Figure 5.15 The Russian Bleeding Disorders Market: Revenue Forecast ($m), 2013-2024
  • Figure 6.1 Overview of R&D Pipeline for Bleeding Disorders: Candidates Filed for Approval or in Phase III Trials, 2013
  • Figure 7.1 Leading Companies of the Bleeding Disorders Market: Market Share (%), 2012
  • Figure 10.1 The World Market for Bleeding Disorders by Disorder: Comparison of Revenues ($m), 2012-2024
  • Figure 10.2 Leading Drugs of the Bleeding Disorders Market: Comparison of Revenues ($m), 2012, 2018 and 2024
  • Figure 10.3 Leading National Markets for Bleeding Disorders: Comparison of Revenues ($m), 2012, 2018 and 2024

Companies Listed

  • Amgen
  • AryoGen Biopharma
  • Asklepios Biopharmaceuticals
  • Baxter
  • Bayer
  • Beijing Northland Biotech
  • Biogen Idec
  • Brazilian Ministry of Health
  • Canadian Haemophilia Society
  • Cangene Corporation
  • Catalyst Biosciences
  • Chatham Therapeutics
  • CSL Behring
  • Eisai
  • Empresa Brasileira de Hemoderivadose Biotechnologia
  • European Medicines Agency (EMA)
  • Food and Drug Administration (US FDA)
  • Genetics Institute
  • GlaxoSmithKline (GSK)
  • Green Cross Corporation
  • Grifols Biologicals
  • Haemophilia Centres of England, Scotland, Northern Ireland or Wales
  • Haemophilia Treatment Centre Collaborative Network of China (HTCCNC)
  • Haemophilialife
  • Hemobrás
  • Inspiration Biopharmaceuticals
  • Ipsen Pharma
  • Italian Association of Haemophilia Centres (AICE)
  • Johns Hopkins Medicine
  • Ligand Pharmaceuticals
  • National Health Service (NHS)
  • National Heart, Lung and Blood Institute
  • Nektar Therapeutics
  • Novo Nordisk
  • Octapharma
  • Pfizer
  • Shenyang Sunshine Pharmaceutical Co.
  • Spanish Haemophilia Society
  • Swedish Orphan Biovitrum
  • United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO)
  • US Food and Drug Administration (FDA)
  • World Federation of Haemophilia
Back to Top